| [1] |
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014(6):99-109.
|
| [2] |
Shen HX, Song HW, Xu XJ, et al. Clinical epidemiological survey of gallbladder carcinoma in northwestern China, 2009-2013: 2379 cases in 17 centers[J]. Chronic Dis Transl Med, 2017, 3(1):60-66.
|
| [3] |
Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges[J]. Nat Rev Drug Discov, 2010, 9(10):775-789.
|
| [4] |
Chandra V, Kim JJ, Mittal B, et al. MicroRNA aberrations: an emerging field for gallbladder cancer management[J]. World J Gastroenterol, 2016, 22(5):1787-1799.
|
| [5] |
Zhou H, Guo W, Zhao Y, et al. MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer[J]. Cancer Sci, 2014, 105(8):956-965.
|
| [6] |
Pais-Costa SR, Farah JF, Artigiani-Neto R, et al. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein imunnoexpression on prognostic of resected gallbladder carcinoma[J]. Arq Bras Cir Dig, 2014, 27(2):126-132.
|
| [7] |
Kirpotin DB, Noble CO, Hayes ME, et al. Building and characterizing antibody-targeted lipidic nanotherapeutics[J]. Methods Enzymol, 2012(502):139-166.
|
| [8] |
Juang V, Lee HP, Lin AM, et al. Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells[J]. Int J Nanomedicine, 2016(11):6047-6064.
|
| [9] |
Ramamoorth M, Narvekar A. Non viral vectors in gene therapy-an overview[J]. J Clin Diagn Res, 2015, 9(1):GE1-6.
|
| [10] |
Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer[J]. Int J Nanomedicine, 2014(9):467-483.
|
| [11] |
Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2010, 2(1):99-112.
|
| [12] |
Goodwin T, Huang L. Nonviral vectors: we have come a long way[J]. Adv Genet, 2014(88):1-12.
|
| [13] |
Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications[J]. Nano Lett, 2010, 10(9):3223-3230.
|
| [14] |
Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy[J]. Nat Rev Genet, 2014, 15(8):541-555.
|
| [15] |
Mortensen JH, Jeppesen M, Pilgaard L, et al. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme[J]. J Drug Deliv, 2013:209205.
|
| [16] |
Kuai JH, Wang Q, Zhang AJ, et al. Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently[J]. World J Gastroenterol, 2018, 24(3):351-359.
|
| [17] |
Yamada Y, Hidaka H, Seki N, et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma[J]. Cancer Sci, 2013, 104(3):304-312.
|
| [18] |
Dang Z, Xu WH, Lu P, et al. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma[J]. Int J Biol Sci, 2014, 10(7):733-745.
|
| [19] |
Shin JY, Kim YI, Cho SJ, et al. MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer[J]. PLoS One, 2014, 9(1):e85205.
|
| [20] |
Tang W, Jiang Y, Mu X, et al. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression[J]. Cell Signal, 2014, 26(7):1420-1426.
|